Get notified when NAMS files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Immediate Dilution of $17.44 Per Ordinary Share (new) — New investors pay $24.50 per share while the as-adjusted net tangible book value is only $7.43, resulting in substantial immediate dilution.
  • No Public Trading Market For the Pre-funded Warrants (new) — The pre-funded warrants will not be listed on any exchange and the company does not expect a market to develop, severely limiting their liquidity.
  • Certain of Our Executive Officers and Shareholders May Sell Up to 610,000 Ordinary Shares and 2,897,299 Ordinary Shares, Respectively, Following the Offering (new) — Insiders have pre-arranged trading plans that allow significant share sales shortly after the offering, potentially pressuring the stock price.
  • We May Sell Ordinary Shares For Gross Proceeds of Up to $150.0 Million From Time to Time Through an 'at-the-market' Equity Offering Program (new) — An active at-the-market program permits ongoing share sales, creating additional dilution risk for investors.
NASDAQ: NAMS NewAmsterdam Pharma Co N.V. 424B5

NewAmsterdam Pharma prices $393.4M follow-on offering at $24.50 per share to fund obicetrapib development

Filed December 13, 2024 · ~2 min read

Key Changes

  • high

    The company will receive approximately $393.4 million in net proceeds, or $452.6 million if underwriters fully exercise their option to purchase additional shares.

    Use of Proceeds verify on EDGAR →
  • high

    Net proceeds are earmarked primarily for continued development and commercial preparedness of obicetrapib, with the remainder for working capital and general corporate purposes.

    Use of Proceeds verify on EDGAR →
  • high

    New investors face immediate dilution of $17.44 per share, as the offering price far exceeds the as-adjusted net tangible book value of $7.43 per share.

3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (ORCL 10-Q) is open in full — no account needed.

Partner

Trade NAMS commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?

Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify